Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, ...

As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...

The FDA is mired in uncertainty with some staffers losing their jobs over the weekend and more potentially to come, vaccines ...

A second federal judge paused Trump's order against gender-affirming care for youth. ( AP) Johnson & Johnson aims to have a ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

Robert F. Kennedy Jr. has taken office as HHS secretary, which could impact the healthcare sector, including ETFs with ...

The U.S. FDA paused Moderna's norovirus vaccine trial due to a rare side effect. U.S. Health Secretary Robert F. Kennedy Jr's initiatives may face budget cuts. Wyoming reports a human bird flu case.

Recent health news highlights US FDA's hold on Moderna's norovirus vaccine trial due to a side-effect case, Robert F. Kennedy ...

Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...